PMID- 35572824
OWN - NLM
STAT- MEDLINE
DCOM- 20220519
LR  - 20230728
IS  - 1748-6718 (Electronic)
IS  - 1748-670X (Print)
IS  - 1748-670X (Linking)
VI  - 2022
DP  - 2022
TI  - Effect of Yiqi Huayu Pinggan Zishen Formula Combined with Valsartan in the 
      Treatment of Hypertension and Its Effect on MMP-9, Ang II, and MCP-1.
PG  - 7982023
LID - 10.1155/2022/7982023 [doi]
LID - 7982023
AB  - OBJECTIVE: To explore the effect of Yiqi Huayu Pinggan Zishen recipe combined 
      with valsartan in the treatment of hypertension and its effect on MMP-9, Ang II, 
      and MCP-1. METHODS: About 100 patients with hypertension treated in our hospital 
      from March 2020 to April 2021 were enrolled. All patients were arbitrarily 
      assigned to the control group and the study group. The former group was cured 
      with valsartan, and the latter group was cured with Yiqi Huayu Pinggan Zishen 
      recipe combined with valsartan. The curative effect, blood pressure level, renal 
      function index, serum matrix metalloproteinase-9 (MMP-9), monocyte 
      chemoattractant protein-1 (MCP-1), angiotensin II (Ang II) level, traditional 
      Chinese medicine (TCM) syndrome score, and the incidence of adverse reactions 
      were compared. RESULTS: First of all, we compared the curative effects; the study 
      group exhibited remarkably effective in 44 cases and effective in 6 cases, and 
      the effective rate was 100.00%, while in the control group, 24 cases were 
      markedly effective, 16 cases were effective, and 5 cases were ineffective; the 
      effective rate was 90.00%. The curative effect in the study group was higher (P < 
      0.05). Secondly, we compared the blood pressure level. Before treatment, there 
      was no remarkable difference (P > 0.05). After treatment, the blood pressure of 
      the two groups decreased. The systolic blood pressure and diastolic blood 
      pressure of the study group were lower (P < 0.05). In terms of renal function 
      indexes, the levels of blood urine nitrogen (BUN), Cr, and beta 2-MG in the study 
      group were lower, while the level of eGFR in the study group was higher (P < 
      0.05). The serum levels of MMP-9, MCP-1, and Ang II decreased. Of note, the 
      levels of serum MMP-9, MCP-1, and Ang II in the study group were lower (P < 
      0.05). After treatment, the TCM syndrome scores decreased, and the study group 
      was lower (P < 0.05). Finally, we compared the incidence of adverse reactions. 
      The incidence of adverse reactions in the study group was lower (P < 0.05). 
      CONCLUSION: Yiqi Huayu Pinggan Zishen recipe combined with valsartan in the 
      treatment of hypertension can remarkably reduce the clinical symptoms, enhance 
      the renal function, strengthen the therapeutic effect, promote the ability of 
      independent movement, and reduce the levels of serum MMP-9, MCP-1, and Ang II 
      with high safety, which has the value of clinical application.
CI  - Copyright (c) 2022 Jing Yan et al.
FAU - Yan, Jing
AU  - Yan J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, 
      Sichuan Province, China.
FAU - Li, Defeng
AU  - Li D
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, 
      Sichuan Province, China.
FAU - Liu, Qin
AU  - Liu Q
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, 
      Sichuan Province, China.
FAU - Xie, Yuanlan
AU  - Xie Y
AUID- ORCID: 0000-0002-1018-4849
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, 
      Sichuan Province, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20220506
PL  - United States
TA  - Comput Math Methods Med
JT  - Computational and mathematical methods in medicine
JID - 101277751
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 11128-99-7 (Angiotensin II)
RN  - 80M03YXJ7I (Valsartan)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
RIN - Comput Math Methods Med. 2023 Jul 19;2023:9819575. PMID: 37503373
MH  - Angiotensin II/therapeutic use
MH  - Antihypertensive Agents/adverse effects
MH  - Chemokine CCL2/therapeutic use
MH  - *Drugs, Chinese Herbal/adverse effects
MH  - Humans
MH  - *Hypertension/drug therapy
MH  - Matrix Metalloproteinase 9/therapeutic use
MH  - Syndrome
MH  - Valsartan/therapeutic use
PMC - PMC9106505
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/05/17 06:00
MHDA- 2022/05/20 06:00
PMCR- 2022/05/06
CRDT- 2022/05/16 04:18
PHST- 2022/02/16 00:00 [received]
PHST- 2022/02/28 00:00 [revised]
PHST- 2022/04/06 00:00 [accepted]
PHST- 2022/05/16 04:18 [entrez]
PHST- 2022/05/17 06:00 [pubmed]
PHST- 2022/05/20 06:00 [medline]
PHST- 2022/05/06 00:00 [pmc-release]
AID - 10.1155/2022/7982023 [doi]
PST - epublish
SO  - Comput Math Methods Med. 2022 May 6;2022:7982023. doi: 10.1155/2022/7982023. 
      eCollection 2022.